As illustrated in Fig. 4A–H, AIGS exhibited dramatically higher accuracy than these features, including age, stage, gender, T, N, M, grade, intravesical therapy, systemic chemotherapy, smoking, BCG treatment, platinum therapy, neoadjuvant chemotherapy, FGFR3, p53, RAS, and RB1 mutations, revealing that our AIGS potential to be a promising tool in evaluating the prognosis risk of BLCA. The gene discussed is RB1; the disease is bladder transitional cell carcinoma.